跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
找到 5,939 条关于
“FH-POISE DRT”
全部
5,939
临床试验
4,686
药物
488
机构
126
资讯
639
7个月前
Forus Health Receives CDSCO Approval for AI-Powered Diabetic Retinopathy Screening Tool in India
去年
Lenvatinib-Tislelizumab Combo Shows Promising 93% Response Rate in Rare Hereditary Kidney Cancer
10个月前
Singapore Launches Phase III of National Precision Medicine Programme to Enroll 400,000 Patients
去年
AHA Advocates for Expanded Lipoprotein Apheresis Use in High-Risk Cardiovascular Patients
2年前
Lenvatinib and Pembrolizumab Combination Shows Promise in Non-Clear Cell Renal Cell Carcinoma Subtypes
去年
Obicetrapib Demonstrates Significant LDL-C Reduction in HeFH Patients in Phase III BROOKLYN Trial
去年
Esperion Advances Bempedoic Acid to Phase 3 Trials for Pediatric Familial Hypercholesterolemia
去年
Novartis Secures Pan-Canadian Agreement for Leqvio Access in Familial Hypercholesterolemia
去年
Obicetrapib Shows Promise in Lowering LDL Cholesterol and Lp(a) in HeFH Patients
去年
Wave Life Sciences Advances Obesity and Cardiometabolic Programs with RNA Therapies
第 1 页,共 64 页
上一页
下一页